MedTrace Logo

Antibody Response to Influenza Vaccine in Patients With Sarcoidosis

NCT00828828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2009-05-21

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of influenza vaccine (antibody response) in patients with sarcoidosis.

Conditions

  • Pulmonary Sarcoidosis

Interventions

BIOLOGICAL

Influenza Vaccine

One 0.5 ml dose of influenza vaccine injected intramuscular.

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Maryam Keshtkar-Jahromi, MD, MPH · Clinical Research & Development Center, Shahid Modarres Hospital, Shahid Beheshti University (MC), Tehran, Iran

  • Sasan Tavana, MD · Clinical Research & Developement Center, Shahid Modares Hospital,Shahid Beheshti University (MC), Tehran, Iran

  • Marzieh Keshtkar-Jahromi, MD · Clinical Research & Developement Center, Shahid Modares Hospital, Shahid Beheshti University (MC), Tehran, Iran

  • Amirsoheil Talebian, MD · Clinical Research & Developement Center, Shahid Modares Hospital,Shahid Beheshti University (MC), Tehran, Iran

  • Mohammad Rahnavardi, MD · Clinical Research & Developement Center, Shahid Modares Hospital,Shahid Beheshti University (MC), Tehran, Iran

  • Talat Mokhtari-Azad, PhD · School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-02-28
Completion
2009-05-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00828828 on ClinicalTrials.gov